tiprankstipranks
Trending News
More News >
IDT Australia Limited (AU:IDT)
ASX:IDT
Australian Market
Advertisement

IDT Australia Limited (IDT) AI Stock Analysis

Compare
4 Followers

Top Page

AU:IDT

IDT Australia Limited

(Sydney:IDT)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 4o)
Rating:41Neutral
Price Target:
AU$0.00
▼(-100.00% Downside)
The overall stock score is primarily impacted by the company's weak financial performance, characterized by consistent losses and negative cash flows. Technical analysis further supports a bearish outlook, with the stock trading below key moving averages and showing negative momentum indicators. Valuation metrics are also unfavorable, with a negative P/E ratio and no dividend yield, making the stock less attractive to investors.

IDT Australia Limited (IDT) vs. iShares MSCI Australia ETF (EWA)

IDT Australia Limited Business Overview & Revenue Model

Company DescriptionIDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. It offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services. The company also provides project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs, as well as pharmaceutical development services in various dosage forms. In addition, it offers medicinal cannabis products, as well as various contract manufacturing services. The company was founded in 1975 and is headquartered in Boronia, Australia.
How the Company Makes MoneyIDT Australia Limited generates revenue primarily through the manufacturing and sale of pharmaceutical products. The company produces active pharmaceutical ingredients (APIs) and finished dosage forms, which are sold to pharmaceutical companies, hospitals, and other healthcare providers. Additionally, IDT offers contract manufacturing services, leveraging its advanced production facilities to produce pharmaceuticals for third parties. The company may also engage in partnerships and collaborations with other pharmaceutical firms to enhance its product offerings and market reach, contributing to its revenue streams.

IDT Australia Limited Financial Statement Overview

Summary
IDT Australia Limited is facing significant financial challenges, with consistent losses and negative cash flows. While there is some revenue growth, profitability and liquidity issues are prominent. The balance sheet shows increased leverage, which could pose risks if not managed carefully. Overall, the financial health of the company is weak, and strategic changes may be needed to improve performance.
Income Statement
35
Negative
IDT Australia Limited has shown some revenue growth, with a 5.28% increase in the latest year. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin has also declined compared to previous years, suggesting challenges in cost management or pricing power.
Balance Sheet
45
Neutral
The company's debt-to-equity ratio has increased, indicating higher leverage, but it remains relatively low compared to industry standards. The return on equity is negative, reflecting ongoing losses. However, the equity ratio is stable, suggesting a solid asset base relative to equity.
Cash Flow
30
Negative
IDT Australia Limited's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow growth rate is negative, and the operating cash flow to net income ratio indicates inefficiencies in converting income into cash. This poses liquidity risks.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue19.77M19.77M13.23M6.93M12.11M15.99M
Gross Profit9.69M9.69M10.42M-3.53M2.82M4.88M
EBITDA-6.54M-6.54M-5.56M-8.83M-340.00K2.75M
Net Income-8.06M-8.06M-5.41M-8.50M-1.16M2.10M
Balance Sheet
Total Assets36.92M36.92M31.37M28.29M30.08M34.13M
Cash, Cash Equivalents and Short-Term Investments4.11M4.11M904.00K4.43M9.21M6.93M
Total Debt10.40M10.40M4.47M740.00K881.00K766.00K
Total Liabilities15.03M15.03M7.93M4.15M3.46M6.51M
Stockholders Equity21.89M21.89M23.44M24.14M26.63M27.61M
Cash Flow
Free Cash Flow-7.55M-7.55M-10.30M-8.42M1.95M-156.00K
Operating Cash Flow-6.25M-6.25M-9.60M-7.90M2.86M370.00K
Investing Cash Flow-4.50M-4.50M-1.09M-522.00K-912.00K-526.00K
Financing Cash Flow10.75M10.75M6.77M3.64M337.00K224.00K

IDT Australia Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.06
Price Trends
50DMA
0.06
Negative
100DMA
0.08
Negative
200DMA
0.09
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
39.93
Neutral
STOCH
27.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDT, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 39.93 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IDT.

IDT Australia Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
AU$46.39M12.967.64%2.86%0.13%-12.90%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
AU$80.55M715.000.19%17.82%
47
Neutral
$43.89M-289.70%-4.27%33.91%
41
Neutral
AU$24.40M-35.58%45.30%-24.18%
41
Neutral
AU$19.03M-218.38%-47.30%82.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:IDT
IDT Australia Limited
0.06
-0.06
-50.00%
AU:NXS
Next Science Ltd
0.15
-0.05
-23.08%
AU:LGP
Little Green Pharma Ltd.
0.14
-0.02
-12.50%
AU:MVP
Medical Developments International Limited
0.72
0.29
67.44%
AU:AGH
Althea Group Holdings Ltd.
0.02
-0.03
-60.00%
AU:VIT
Cronos Australia Ltd.
0.07
-0.04
-36.36%

IDT Australia Limited Corporate Events

IDT Australia Limited Announces Cessation of Securities
Jul 15, 2025

IDT Australia Limited announced the cessation of 861,000 ordinary fully paid securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for its market positioning and stakeholder interests.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 03, 2025